Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Chauchet, Adrien ^a   Michallet, Anne Sophie ^a   Berger, Françoise ^a   Bedgedjian, Isabelle ^b   Deconinck, Eric ^c   Sebban, Catherine ^d   Antal, Daciana ^e   Orfeuvre, Hubert ^f   Corront, Bernadette ^g   Petrella, Tony ^h   Hacini, Maya ⁱ   Bouteloup, Marie ^a   Salles, Gilles ^a   Coiffier, Bertrand ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Department of Anatomopathology ^*  (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d CENTRE LÉON BÉRARD   (France)

^e CENTRE HOSPITALIER DE ROANNE   (France)

^f Centre Hospitalier de Bourg en Bresse   (France)

^g Centre Hospitalier de la Region d'Annecy   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE CHAMBÉRY   (France)

Author keywords

Complete response; Extra nodal NK T cell; KPI index; Radiotherapy plus chemotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84861953717     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-27     Document Type: Article

References (31)

1. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, et al. Eur J Cancer 2005 41 1402 1408 10.1016/j.ejca.2005.03.010 15963893
2. NK-cell neoplasms in Japan. Oshimi K, Kawa K, Nakamura S, Suzuki R, Suzumiya J, Yamaguchi M, Kameoka J, Tagawa S, Imamura N, Ohshima K, et al. Hematology 2005 10 237 245 10.1080/10245330400026162 16019472
3. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Quintanilla-Martinez L, Franklin JL, Guerrero I, Krenacs L, Naresh KN, Rama-Rao C, Bhatia K, Raffeld M, Magrath IT, Hum Pathol 1999 30 849 855 10.1016/S0046-8177(99)90147-8 10414505
4. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Muller-Hermelink HK, Ann Oncol 2002 13 140 149 10.1093/annonc/mdf033 11863096
5. Extranodal NK/T-cell lymphoma, nasal type. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues International Agency for Research on Cancer, Lyon, France, Swerdlow SH, Campo E, Harris NL, 2008
6. Classification of cytotoxic T-cell and natural killer cell lymphomas. Jaffe ES, Krenacs L, Raffeld M, Semin Hematol 2003 40 175 184 10.1016/S0037-1963(03)00132-X 12876666
7. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J, et al. Eur J Haematol 2008 80 55 60 18028433
8. Progress in understanding and managing natural killer-cell malignancies. Oshimi K, Br J Haematol 2007 139 532 544 10.1111/j.1365-2141.2007.06835.x 17916099
9. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, et al. J Clin Oncol 2006 24 612 618 10.1200/JCO.2005.04.1384 16380410
10. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Pagano L, Gallamini A, Trape G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, et al. Ann Oncol 2006 17 794 800 10.1093/annonc/mdl015 16497823
11. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST, Lancet Oncol 2009 10 1093 1101 10.1016/S1470- 2045(09)70265-7 19880063
12. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Briere J, Baglin AC, Cheze S, Bosq J, et al. Blood 2007 109 2183 2189 10.1182/blood-2006-07-033142 17077322
13. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL, Blood 2004 103 216 221 10.1182/blood-2003-05-1401 12933580
14. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Ng SB, Lai KW, Murugaya S, Lee KM, Loong SL, Fook-Chong S, Tao M, Sng I, Mod Pathol 2004 17 1097 1107 10.1038/modpathol.3800157 15195107
15. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J, Int J Hematol 2003 78 163 167 10.1007/BF02983387 12953813
16. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, Okada J, Itami J, Ito H, Cancer 2006 106 609 615 10.1002/cncr.21656 16369986
17. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R, Blood 2009 113 3931 3937 10.1182/blood-2008-10- 185256 19029440
18. CD56+ NK lymphomas: clinicopathological features and prognosis. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, Todd D, Ho FC, Br J Haematol 1997 97 821 829 10.1046/j.1365-2141.1997.1462962.x 9217183
19. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, et al. Ann Oncol 21 1032 1040
20. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, et al. Blood 95
21. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Barrionuevo C, Zaharia M, Martinez MT, Taxa L, Misad O, Moscol A, Sarria G, Guerrero I, Casanova L, Flores C, Zevallos-Giampietri EA, Appl Immunohistochem Mol Morphol 153 451 485
22. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Kim K, Chie EK, Kim CW, Kim IH, Park CI, Jpn J Clin Oncol 2005 35 1 5 10.1093/jjco/hyi006 15681596
23. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Kuo TT, Shih LY, Tsang NM, Int J Surg Pathol 2004 12 375 387 10.1177/106689690401200410 15494863
24. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Huang MJ, Jiang Y, Liu WP, Li ZP, Li M, Zhou L, Xu Y, Yu CH, Li Q, Peng F, et al. Int J Radiat Oncol Biol Phys 2008 70 166 174 10.1016/j.ijrobp.2007.05.073 17919841
25. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, et al. J Clin Oncol 2006 24 181 189 10.1200/JCO.2005.03. 2573 16382127
26. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, et al. J Clin Oncol 2009 27 5594 5600 10.1200/JCO.2009.23.8295 19805668
27. L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma. Obama K, Tara M, Niina K, Int J Hematol 2003 78 248 250 10.1007/BF02983802 14604284
28. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J, Hematol Oncol 2006 24 28 32 10.1002/hon.765 16323259
29. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma, N Engl J Med 1993 329 987 994 8141877
30. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, et al. Blood 2004 103 2474 2479 10.1182/blood-2003-09-3080 14645001
31. The International Harmonization Project for response criteria in lymphoma clinical trials. Cheson BD, Hematol Oncol Clin North Am 2007 21 841 854 10.1016/j.hoc.2007.06.011 17908623